Access the full text.
Sign up today, get DeepDyve free for 14 days.
K. Öberg (2018)
Management of functional neuroendocrine tumors of the pancreas.Gland surgery, 7 1
M. Diez, A. Teule, R. Salazar (2013)
Gastroenteropancreatic neuroendocrine tumors: diagnosis and treatmentAnnals of Gastroenterology : Quarterly Publication of the Hellenic Society of Gastroenterology, 26
B. Oronsky, P. Ma, D. Morgensztern, C. Carter (2017)
Nothing But NET: A Review of Neuroendocrine Tumors and CarcinomasNeoplasia (New York, N.Y.), 19
E. Jun, Song-Cheol Kim, K. Song, D. Hwang, J. Lee, S. Shin, Seung‐Mo Hong, Kwang-Min Park, Young-Joo Lee (2017)
Diagnostic value of chromogranin A in pancreatic neuroendocrine tumors depends on tumor size: A prospective observational study from a single instituteSurgery, 162
D. Halperin, L. Huynh, J. Beaumont, B. Cai, T. Totev, R. Bhak, M. Duh, M. Neary, D. Cella (2018)
Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndromeMedicine, 97
(2019)
Analysis of realworld treatment patterns, healthcare resource utilization, and costs between octreotide and lanreotide among patients with neuroendocrine tumors
C. Seo, E. Horodniceanu, R. Shah, G. Goldstein, D. Ray, Bonita Bennett, A. Phan, K. McCarrier (2022)
A qualitative study to understand the experience of somatostatin analog treatments from the perspective of patients with neuroendocrine tumorsSupportive Care in Cancer, 30
M. Shah, W. Goldner, A. Benson, E. Bergsland, L. Blaszkowsky, P. Brock, J. Chan, Satya Das, P. Dickson, P. Fanta, T. Giordano, T. Halfdanarson, D. Halperin, Jin He, A. Heaney, M. Heslin, F. Kandeel, A. Kardan, S. Khan, B. Kuvshinoff, C. Lieu, Kimberly Miller, V. Pillarisetty, D. Reidy, S. Salgado, Shagufta Shaheen, H. Soares, M. Soulen, J. Strosberg, C. Sussman, N. Trikalinos, Nataliya Uboha, Namrata Vijayvergia, T. Wong, B. Lynn, Cindy Hochstetler (2021)
Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.Journal of the National Comprehensive Cancer Network : JNCCN, 19 7
S. Faivre, P. Niccoli, D. Castellano, J. Valle, P. Hammel, J. Raoul, A. Vinik, E. Cutsem, Y. Bang, S. Lee, I. Borbath, C. Lombard-Bohas, P. Metrakos, D. Smith, J-S. Chen, P. Ruszniewski, J. Seitz, S. Patyna, D. Lu, K. Ishak, E. Raymond (2016)
Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized studyAnnals of Oncology, 28
(SAS/ACCESS® 9.4 Interface to ADABAS: Reference. Cary: SAS Institute Inc; 2013.)
SAS/ACCESS® 9.4 Interface to ADABAS: Reference. Cary: SAS Institute Inc; 2013.SAS/ACCESS® 9.4 Interface to ADABAS: Reference. Cary: SAS Institute Inc; 2013., SAS/ACCESS® 9.4 Interface to ADABAS: Reference. Cary: SAS Institute Inc; 2013.
P. Ruszniewski, J. Valle, C. Lombard-Bohas, D. Cuthbertson, P. Perros, L. Holubec, G. Fave, Denis Smith, P. Niccoli, P. Maisonobe, P. Atlan, M. Caplin (2016)
Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study.Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 48 5
(2013)
4 Interface to ADABAS: Reference. Cary: SAS Institute Inc
E. Eisenhauer, P. Therasse, J. Bogaerts, L. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, Lawrence Rubinstein, L. Shankar, L. Dodd, Robert Kaplan, D. Lacombe, J. Verweij (2009)
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).European journal of cancer, 45 2
E. Wolin, J. Leyden, G. Goldstein, T. Kolarova, R. Hollander, R. Warner (2017)
Patient-Reported Experience of Diagnosis, Management, and Burden of Neuroendocrine TumorsPancreas, 46
M. Bharmal, K. Payne, M. Atkinson, M. Desrosiers, D. Morisky, E. Gemmen (2009)
Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medicationsHealth and Quality of Life Outcomes, 7
A. Frilling, G. Åkerström, M. Falconi, M. Pavel, J. Ramos, M. Kidd, I. Modlin (2012)
Neuroendocrine tumor disease: an evolving landscape.Endocrine-related cancer, 19 5
M. Caplin, Mohid Khan, F. El-Khouly, P. Davies, C. Toumpanakis (2011)
Long‐term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel)Alimentary Pharmacology & Therapeutics, 34
A. Vinik, E. Wolin, N. Liyanage, E. Gomez-Panzani, G. Fisher (2016)
EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 22 9
M. Palazzo, C. Lombard-Bohas, G. Cadiot, T. Matysiak-Budnik, V. Rebours, M. Vullierme, A. Couvelard, O. Hentic, P. Ruszniewski (2013)
Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumorsEuropean Journal of Gastroenterology & Hepatology, 25
O. Clark, A. Benson, J. Berlin, M. Choti, G. Doherty, P. Engstrom, J. Gibbs, M. Heslin, A. Kessinger, M. Kulke, L. Kvols, R. Salem, L. Saltz, M. Shah, S. Shibata, J. Strosberg, James Yao (2009)
NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors.Journal of the National Comprehensive Cancer Network : JNCCN, 7 7
Feng Yang, C. Jin, D. Fu (2014)
Lanreotide in metastatic enteropancreatic neuroendocrine tumors.The New England journal of medicine, 371 16
J. Ramage, P. Punia, O. Faluyi, A. Frilling, T. Meyer, Ruby Saharan, J. Valle (2019)
Observational Study to Assess Quality of Life in Patients with Pancreatic Neuroendocrine Tumors Receiving Treatment with Everolimus: The OBLIQUE Study (UK Phase IV Trial)Neuroendocrinology, 108
Governor, Kody Kinsley, Secretary, Mark Payne (2020)
Health and Human ServicesCongress and the Nation 2013-2016, Volume XIV: Politics and Policy in the 113th and 114th Congresses
J. Strosberg, A. Benson, L. Huynh, M. Duh, J. Goldman, V. Sahai, A. Rademaker, M. Kulke (2014)
Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study.The oncologist, 19 9
M. Raphael, D. Chan, C. Law, S. Singh (2017)
Principles of diagnosis and management of neuroendocrine tumoursCanadian Medical Association Journal, 189
(2020)
Patient experience with somatostatin analog treatments for neuroendocrine tumors: insight from qualitative interviews
(2018)
Framework for FDA's Real-World Evidence Program
A. Faggiano, R. Modica, F. Calzo, L. Camera, V. Napolitano, B. Altieri, F. Cicco, Fialomena Bottiglieri, F. Sesti, G. Badalamenti, A. Isidori, A. Colao (2019)
Lanreotide therapy vs active surveillance in MEN1-related pancreatic neuroendocrine tumors <2 cm.The Journal of clinical endocrinology and metabolism
R. García-Carbonero, J. Capdevila, G. Crespo-Herrero, J. Díaz-Pérez, M. Prado, V. Orduña, I. Sevilla-García, C. Villabona-Artero, A. Beguiristain-Gómez, M. Llanos-Muñoz, Mónica Marazuela, C. Alvarez-Escola, D. Castellano, Eduardo Vilar, P. Jiménez-Fonseca, A. Teule, J. Sastre-Valera, M. Benavent-Viñuelas, A. Monleón, R. Salazar (2010)
Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).Annals of oncology : official journal of the European Society for Medical Oncology, 21 9
J. Stockman (2012)
Everolimus for Advanced Pancreatic Neuroendocrine TumorsYearbook of Pediatrics, 2012
A. Berner, C. Pipinikas, A. Ryan, H. Dibra, Ismail Moghul, A. Webster, T. Luong, C. Thirlwell (2019)
Diagnostic Approaches to Neuroendocrine Neoplasms of Unknown Primary SiteNeuroendocrinology, 110
A. Klink, B. Feinberg, Hsing-Ting Yu, D. Ray, S. Pulgar, A. Phan, A. Vinik (2019)
Patterns of Care Among Real-World Patients with Metastatic Neuroendocrine Tumors.The oncologist
(2020)
Lanreotide therapy vs active surveillance in MEN1-related pancreatic neuroendocrine tumors < 2 centimetersJ Clin Endocrinol Metab, 105
K. Kim, K. Krajewski, M. Nishino, J. Jagannathan, A. Shinagare, S. Tirumani, N. Ramaiya (2013)
Update on the management of gastroenteropancreatic neuroendocrine tumors with emphasis on the role of imaging.AJR. American journal of roentgenology, 201 4
M. Pavel, J. Cwikła, C. Lombard-Bohas, I. Borbath, T. Shah, U. Pape, J. Capdevila, F. Panzuto, Xuan-Mai Thanh, A. Houchard, P. Ruszniewski (2021)
Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results.European journal of cancer, 157
(2019)
Highlights of US prescribing information: Somatuline Depot (lanreotide) injection, for subcutaneous use
M. Caplin, M. Pavel, A. Phan, J. Cwikła, E. Sedláčková, X. Thanh, E. Wolin, P. Ruszniewski, O. investigators (2020)
Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension studyEndocrine, 71
R. Basuroy, C. Bouvier, J. Ramage, M. Sissons, R. Srirajaskanthan (2018)
Delays and routes to diagnosis of neuroendocrine tumoursBMC Cancer, 18
C. Barbosa, M. Balp, K. Kulich, N. Germain, D. Rofail (2012)
A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistencePatient preference and adherence, 6
C. Deroose, E. Hindié, E. Kebebew, B. Goichot, K. Pacak, D. Taïeb, A. Imperiale (2016)
Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future DirectionsThe Journal of Nuclear Medicine, 57
M. Kulke, L. Siu, J. Tepper, G. Fisher, D. Jaffe, D. Haller, L. Ellis, J. Benedetti, E. Bergsland, T. Hobday, E. Cutsem, J. Pingpank, K. Oberg, S. Cohen, M. Posner, James Yao (2011)
Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 7
Jared Adams, D. Ray, R. Willmon, S. Pulgar, A. Dasari (2019)
Living With Neuroendocrine Tumors: Assessment of Quality of Life Through a Mobile ApplicationJCO Clinical Cancer Informatics, 3
(NCCN. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. 2015.)
NCCN. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. 2015.NCCN. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. 2015., NCCN. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. 2015.
A. Dasari, Chan Shen, D. Halperin, Bo Zhao, Shouhao Zhou, Ying Xu, T. Shih, James Yao (2017)
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United StatesJAMA Oncology, 3
M. Michael, R. García-Carbonero, M. Weber, C. Lombard-Bohas, C. Toumpanakis, R. Hicks (2017)
The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.The oncologist, 22 3
(FDA. Framework for FDA's Real-World Evidence Program. 2018. Available at: https://www.fda.gov/media/120060/download.)
FDA. Framework for FDA's Real-World Evidence Program. 2018. Available at: https://www.fda.gov/media/120060/download.FDA. Framework for FDA's Real-World Evidence Program. 2018. Available at: https://www.fda.gov/media/120060/download., FDA. Framework for FDA's Real-World Evidence Program. 2018. Available at: https://www.fda.gov/media/120060/download.
P. Ryan, A. McBride, D. Ray, S. Pulgar, R. Ramirez, E. Elquza, JP Favaro, G. Dranitsaris (2019)
Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysisJournal of Oncology Pharmacy Practice, 25
A. Rinke, H. Müller, C. Schade-Brittinger, K. Klose, P. Barth, M. Wied, C. Mayer, B. Aminossadati, U. Pape, M. Bläker, J. Harder, C. Arnold, T. Gress, R. Arnold (2009)
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 28
A. Faggiano, S. Maio, C. Mocerino, M. Ottaviano, C. Divitiis, V. Guarnotta, P. Dolce, R. Modica, I. Puliafito, L. Tozzi, A. Sarno, S. Leo, F. Riccardi, G. Palmieri, S. Tafuto, A. Bianco, G. Badalamenti, A. Colao, on Elios (2019)
Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS groupEndocrine, 66
(2011)
Everolimus for advanced pancreatic neuroendocrine tumorsN Engl J Med, 364
Marianne Pavel, K. Öberg, M. Falconi, E. Krenning, A. Sundin, A. Perren, A. Berruti (2020)
Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of oncology : official journal of the European Society for Medical Oncology
Marie Brown, Jennifer Bussell (2011)
Medication adherence: WHO cares?Mayo Clinic proceedings, 86 4
V. Ambrosini, D. Campana, P. Tomassetti, S. Fanti (2012)
68Ga-labelled peptides for diagnosis of gastroenteropancreatic NETEuropean Journal of Nuclear Medicine and Molecular Imaging, 39
T. Aparicio, M. Ducreux, E. Baudin, J. Sabourin, T. Baère, E. Mitry, M. Schlumberger, P. Rougier (2001)
Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours.European journal of cancer, 37 8
(2010)
US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE)
A. Chauhan, Z. Farooqui, L. Murray, H. Weiss, Zin Myint, A. Raajasekar, B. Evers, S. Arnold, L. Anthony (2018)
Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown PrimaryJournal of Oncology, 2018
(2014)
Lanreotide in metastatic enteropancreatic neuroendocrine tumorsN Engl J Med, 371
IntroductionGastroenteropancreatic neuroendocrine tumors (GEP-NETs) can result in symptoms such as diarrhea, flushing, abdominal pain, and fatigue and are often associated with a significant disease burden and poor prognosis. This non-interventional, prospective, observational study evaluated the real-world safety and effectiveness of lanreotide depot, a somatostatin analog (SSA) used to treat GEP-NETs, in a community setting.MethodsIn this prospective, non-interventional study (NCT02730104), adult patients with locally advanced (inoperable), metastatic GEP-NETs treated with lanreotide depot were evaluated by their physician every 6 months from enrollment for 24 months. Clinically defined time to disease progression (TTDP) and overall survival (OS) were estimated for the total population and by primary tumor type (gastrointestinal [GI], pancreatic, unknown origin), and an exploratory analysis determined the rate of progression-free survival (PFS) at 12 and 24 months. Patient satisfaction was evaluated via the Treatment Satisfaction Questionnaire for Medication (TSQM-9), and safety information was recorded.ResultsOf 99 patients, the 24-month PFS rate was 73.7% (95% confidence interval [CI] 63.1–81.7) and 24-month OS rate was 84.2% (95% CI 74.0–90.7). Median TTDP was not reached because few patients experienced disease progression during the study period. The majority of responding patients expressed satisfaction with treatment on each domain of the TSQM-9. Treatment-related adverse events (AEs) occurred in 19.2% of patients, while no serious AEs (SAEs) were related to the study drug.ConclusionsLanreotide depot is an effective and well-tolerated treatment for GEP-NETs in the real-world community setting.Trial registrationClinicalTrials.gov identifier, NCT02730104.
Oncology and Therapy – Springer Journals
Published: Dec 1, 2022
Keywords: GEP-NETs; Lanreotide depot; Neuroendocrine tumors; Oncology; Progression-free survival; Patient satisfaction; Prospective study; Real-world evidence
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.